Soru

Zorluk: OrtaResearch Ethics and Conflicts of Interest

A 32-year-old woman, gravida 2, para 1, is admitted to the labor and delivery unit at 39 weeks gestation in active labor. The attending obstetrician is the principal investigator of a prospective randomized controlled trial evaluating a novel, unapproved combination of uterotonic agents for the management of postpartum hemorrhage. While the patient is in the early stages of labor and fully possesses decision-making capacity, the physician discusses the trial with her. After reviewing the informed consent document, the patient explicitly states, "I do not want to be part of any experiment. I refuse to participate in this study."

Three hours later, the patient has an uncomplicated vaginal delivery of a healthy infant. However, shortly after delivery, she develops severe postpartum hemorrhage that is refractory to uterine massage and standard-of-care medications. The patient rapidly loses a significant amount of blood, becomes hypotensive, and loses consciousness. Her husband, who is at the bedside, is terrified and tells the physician, "Please use that new experimental drug you were talking about earlier! Do whatever it takes to save her life!"

Which of the following is the most appropriate next step regarding the experimental therapy?

  1. A
    Administer the experimental therapy because the patient's surrogate has provided emergency consent.
  2. B
    Administer the experimental therapy because maternal refusal can be overridden in peripartum emergencies.
  3. Withhold the experimental therapy and proceed with standard surgical management.Cevap
  4. D
    Administer the experimental therapy outside the trial and include the data in a retrospective case-control study.
  5. E
    Withhold the experimental therapy and initiate a root cause analysis to formally reprimand the staff for failing to secure trial enrollment.

Cevap

Withhold the experimental therapy and proceed with standard surgical management of postpartum hemorrhage.
The principle of respect for persons requires that capable individuals be allowed to make their own choices regarding research participation. This patient explicitly refused enrollment in the experimental trial while she possessed decision-making capacity. When a patient subsequently loses capacity, a surrogate decision-maker (such as her husband) must exercise substituted judgment, which strictly requires honoring the patient's known prior wishes. A surrogate cannot override a patient's explicit refusal, even in a life-threatening emergency. Therefore, the physician must ethically withhold the experimental therapy and instead proceed with the next steps in standard-of-care management, which for refractory postpartum hemorrhage includes surgical interventions (e.g., balloon tamponade, uterine compression sutures, or hysterectomy).

Adım Adım Çözüm

1
Evaluate the patient's prior stated wishes regarding research participation.
The patient explicitly refused to participate in the experimental trial while she had full decision-making capacity.
Informed consent is a cornerstone of research ethics; capable patients have the absolute right to decline participation in research.
2
Assess the husband's authority as a surrogate decision-maker in this emergency.
Although the husband is the default surrogate, he cannot override the patient's explicit, capacitated refusal of the experimental treatment.
Surrogate decision-makers must exercise substituted judgment, making decisions based on the patient's known values and prior stated wishes, rather than their own desires.
3
Determine the appropriate clinical intervention.
The experimental therapy must be withheld, and the team must escalate to standard-of-care surgical interventions.
Respect for patient autonomy dictates that physicians cannot force experimental research or treatments that have been specifically refused, even in life-threatening situations.

Anahtar Kavram

Respect for patient autonomy and the limits of surrogate decision-making in clinical research.
Bu soruyu puanla